Prespecified BRIGHT-4 analysis (6,016 STEMI, radial primary PCI): bivalirudin vs heparin cut 30-day death/major bleeding in low bleeding risk patients (1.4% vs 2.9%; HR 0.49); higher-risk: 8.1% vs 9.2% (HR 0.88, CI 0.62–1.26, not significant). Absolute interaction P=0.81.
RCTn = 6,016
Qiu et al. Bivalirudin Versus Heparin in Low and Non-Low Bleeding Risk Patients Undergoing Primary PCI for STEMI: The BRIGHT-4 Trial